for NORSE patients (www.norseinstitute.org/norse-registry-2) to promote clinical research with an aim to understand possible causes of NORSE, identify best treatment options and hence improve patient outcomes. Overall, an interprofessional healthcare team approach to managing NORSE will yield the best patient outcomes. This team is comprised of clinicians, specialists, nursing staff, and pharmacists, working collaboratively with open communication lines to achieve the best possible care standard. [Level 5] ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=129235&utm_source=pubmed&utm_campaign=reviews&utm_content=129235) - [Click here for a simplified version.](https://mdsearchlight.com/neurology/new-onset-refractory-status-epilepticus/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=129235) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/129235/?utm_source=pubmed&utm_campaign=comments&utm_content=129235) ## References 1. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015 Oct;56(10):1515-23. \[[PubMed: 26336950](https://pubmed.ncbi.nlm.nih.gov/26336950)\] 2. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ, Shutter L, Sperling MR, Treiman DM, Vespa PM., Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012 Aug;17(1):3-23. \[[PubMed: 22528274](https://pubmed.ncbi.nlm.nih.gov/22528274)\] 3. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011 Oct;134(Pt 10):2802-18. \[[PubMed: 21914716](https://pubmed.ncbi.nlm.nih.gov/21914716)\] 4. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011 Oct;10(10):922-30. \[[PMC free article: PMC3202016](/pmc/articles/PMC3202016/)\] \[[PubMed: 21939901](https://pubmed.ncbi.nlm.nih.gov/21939901)\] 5. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002 Feb;59(2):205-10. \[[PubMed: 11843690](https://pubmed.ncbi.nlm.nih.gov/11843690)\] 6. Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Epilepsia. 2017 Sep;58(9):1533-1541. \[[PubMed: 28681418](https://pubmed.ncbi.nlm.nih.gov/28681418)\] 7. Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand. 2017 Jan;135(1):92-99. \[[PubMed: 27080243](https://pubmed.ncbi.nlm.nih.gov/27080243)\] 8. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012 Aug;135(Pt 8):2314-28. \[[PubMed: 22577217](https://pubmed.ncbi.nlm.nih.gov/22577217)\] 9. Wilder-Smith EP, Lim EC, Teoh HL, Sharma VK, Tan JJ, Chan BP, Ong BK. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap. 2005 Aug;34(7):417-20. \[[PubMed: 16123813](https://pubmed.ncbi.nlm.nih.gov/16123813)\] 10. Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T,